On December 26, 2024, Johnson & Johnson (NYSE: JNJ) announced today that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical.
Click here for more info.
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap.
Many thanks!~
发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权